Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2.

Kim A ReissRosemarie MickMark H O'HaraUrsina TeitelbaumThomas Benjamin KarasicCharles SchneiderStacy CowdenTraci SouthwellJanae RomeoNatallia IzgurZain M HannanRashmi TondonKatherine L NathansonRobert H VonderheideMax M WattenbergGregory BeattySusan M Domchek

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

Maintenance rucaparib is a safe and effective therapy for platinum-sensitive, advanced PC with a PV in BRCA1, BRCA2, or PALB2. The finding of efficacy in patients with gPALB2 and sBRCA2 PVs expands the population likely to benefit from PARPi beyond gBRCA1/2 PV carriers.

Keyphrases

phase ii study
breast cancer risk
randomized controlled trial
gene expression
clinical trial
rectal cancer
double blind